All currency values in $ millions unless otherwise noted
| Income Statement | TTM ~1.4:1 split | DEC 2025 ~15.7:1 split | DEC 2024 |
|---|---|---|---|
| Revenues | |||
| Revenue | $23 | – | $168 |
| General & Administrative | $41 | $34 | $26 |
| Research & Development | $117 | $108 | $83 |
| Total Operating Expenses | $158 | $143 | $110 |
| Operating Income | -$135 | -$143 | $58 |
| EBT (Earnings Before Tax) | – | -$131 | $53 |
| Income Tax Expense | – | $0 | $1 |
| Net Income | |||
| Net Income | -$127 | -$131 | $52 |
| Per Share Data | |||
| Revenue Per Share | $0.38 | – | $61.35 |
| EPS (Basic) | -$12.23 | -$3.05 | $1.42 |
| EPS (Diluted) | -$12.23 | -$3.05 | $1.25 |
| Weighted Avg Shares (Basic) | 59.0M | 43.0M | 2.4M |
| Weighted Avg Shares (Diluted) | 59.0M | 43.0M | 2.7M |
| Shares Outstanding | 59.0M | 43.0M | 2.7M |
Maze Therapeutics (MAZE) financials: revenue, profit and margins
Maze Therapeutics (MAZE) generated about n/a in revenue and -$134 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Maze Therapeutics profitable?+
Maze Therapeutics reported about -$134 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 5 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Aug 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with MAZE
Held by ETFs
MAZE is in 35 US ETFs. The largest of them, with MAZE's weight in each:
Spot a number that looks wrong? Check it in MAZE's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing MAZE
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.